Why China’s Patent System Demands Your Full Attention Now China filed more than 1.5 million patent applications in 2022, making

Executive Summary and Key Findings The USPTO’s Drug Patent and Exclusivity Study, produced in collaboration with the FDA at the

1. What the 505(b)(2) Pathway Actually Is (and What It Isn’t) The 505(b)(2) New Drug Application (NDA) is a hybrid

A technical deep dive for pharma IP teams, portfolio managers, R&D leads, and institutional investors Why Most Generic Drug Strategies

What Branded Generics Actually Are — and Why the Definition Matters for IP Teams The pharmaceutical industry uses ‘branded generic’

Drug repurposing has a dirty secret. For every sildenafil-to-Viagra success story, there are dozens of ventures that got five years

Patent cliffs get all the attention. Divisional patents do the real work. When a blockbuster drug faces loss of exclusivity,

The full playbook of drug patent lifecycle management — and what it costs everyone else Drug companies spend roughly $2.23